Literature DB >> 22576049

[S3 guidelines on diagnostics and therapy of bipolar disorders: development process and essential recommendations].

A Pfennig1, T Bschor, T Baghai, P Bräunig, P Brieger, P Falkai, D Geissler, R Gielen, H Giesler, O Gruber, I Kopp, T D Meyer, K H Möhrmann, C Muche-Borowski, F Padberg, H Scherk, D Strech, M Bauer.   

Abstract

Bipolar disorders are severe psychiatric disorders with extensive individual and health economic consequences. Starting in 2007 the first German evidence and consensus based guideline for diagnostics and treatment of bipolar disorders was developed which holds the potential of increasing confidence of therapists, patients and relatives in the decision-making process and improving healthcare service experiences of patients and relatives. Apart from recommendations for diagnostics and treatment the guidelines provide those for trialogue action, knowledge transfer and self-help and for strategies for healthcare provision of this complex disorder. In the present article the methodology and essential recommendations are outlined and complemented in specific topics by corresponding articles in this special issue. Due to restrictions of the length of this presentation there is the need to refer to the comprehensive version of the guidelines at several points also regarding a detailed discussion of the limitations.

Entities:  

Mesh:

Year:  2012        PMID: 22576049     DOI: 10.1007/s00115-011-3415-3

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  10 in total

1.  Auditing the implementation of SIGN (Scottish Intercollegiate Guidelines Network) clinical guidelines.

Authors:  M Keaney; A R Lorimer
Journal:  Int J Health Care Qual Assur Inc Leadersh Health Serv       Date:  1999

Review 2.  A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression.

Authors:  R Churchill; V Hunot; R Corney; M Knapp; H McGuire; A Tylee; S Wessely
Journal:  Health Technol Assess       Date:  2001       Impact factor: 4.014

3.  Grading quality of evidence and strength of recommendations.

Authors:  David Atkins; Dana Best; Peter A Briss; Martin Eccles; Yngve Falck-Ytter; Signe Flottorp; Gordon H Guyatt; Robin T Harbour; Margaret C Haugh; David Henry; Suzanne Hill; Roman Jaeschke; Gillian Leng; Alessandro Liberati; Nicola Magrini; James Mason; Philippa Middleton; Jacek Mrukowicz; Dianne O'Connell; Andrew D Oxman; Bob Phillips; Holger J Schünemann; Tessa Tan-Torres Edejer; Helena Varonen; Gunn E Vist; John W Williams; Stephanie Zaza
Journal:  BMJ       Date:  2004-06-19

4.  [The concept of the development of S3 guidelines: additional benefit compared to traditional standards, problems and solutions].

Authors:  A Pfennig; I Kopp; D Strech; M Bauer
Journal:  Nervenarzt       Date:  2010-09       Impact factor: 1.214

5.  The Scottish Intercollegiate Guidelines Network (SIGN): an update.

Authors:  G Lowe; Sara Twaddle
Journal:  Scott Med J       Date:  2005-05       Impact factor: 0.729

6.  Medical risk in patients with bipolar disorder and schizophrenia.

Authors:  John W Newcomer
Journal:  J Clin Psychiatry       Date:  2006-11       Impact factor: 4.384

7.  [Development of the evidence-based S3 guideline for diagnosis and therapy of bipolar disorders].

Authors:  Andrea Pfennig; Beate Weikert; Peter Falkai; Thomas Gotz; Ina Kopp; Johanna Sasse; Harald Scherk; Daniel Strech; Michael Bauer
Journal:  Nervenarzt       Date:  2008-04       Impact factor: 1.214

8.  Medical comorbidity in women and men with bipolar disorders: a population-based controlled study.

Authors:  Caroline P Carney; Laura E Jones
Journal:  Psychosom Med       Date:  2006 Sep-Oct       Impact factor: 4.312

Review 9.  Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications.

Authors:  Roger S McIntyre; Jakub Z Konarski; Virginia L Misener; Sidney H Kennedy
Journal:  Ann Clin Psychiatry       Date:  2005 Apr-Jun       Impact factor: 1.567

Review 10.  Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration.

Authors:  R W Licht; H Gijsman; W A Nolen; J Angst
Journal:  Acta Psychiatr Scand       Date:  2008-08-26       Impact factor: 6.392

  10 in total
  19 in total

1.  [S3 guidelines on bipolar disorders are contemporary and important instruments for clinical practice. For].

Authors:  A Pfennig; M Bauer
Journal:  Nervenarzt       Date:  2013-07       Impact factor: 1.214

Review 2.  Assessing the roles of stimulants/stimulant-like drugs and dopamine-agonists in the treatment of bipolar depression.

Authors:  Bernardo Dell'Osso; Terence A Ketter; Laura Cremaschi; Gregorio Spagnolin; A Carlo Altamura
Journal:  Curr Psychiatry Rep       Date:  2013-08       Impact factor: 5.285

Review 3.  [Bipolar disorders in DSM-5].

Authors:  E Severus; M Bauer
Journal:  Nervenarzt       Date:  2014-05       Impact factor: 1.214

Review 4.  [Ketamine as antidepressant: the current study situation].

Authors:  P S Ritter; M Bauer; M Pilhatsch
Journal:  Nervenarzt       Date:  2014-11       Impact factor: 1.214

Review 5.  [Side effects and risk profile of lithium: critical assessment of a systematic review and meta-analysis].

Authors:  T Bschor; M Bauer
Journal:  Nervenarzt       Date:  2013-07       Impact factor: 1.214

6.  Managing the risk of lithium-induced nephropathy in the long-term treatment of patients with recurrent affective disorders.

Authors:  Emanuel Severus; Michael Bauer
Journal:  BMC Med       Date:  2013-02-11       Impact factor: 8.775

7.  [New facts of long-term prophylaxis for bipolar affective disorder].

Authors:  T Bschor; B Müller-Oerlinghausen; G Stoppe; C Hiemke
Journal:  Nervenarzt       Date:  2014-09       Impact factor: 1.214

Review 8.  [Guideline-adherent psychiatric psychotherapeutic treatment of bipolar disorders : Which resources are needed?]

Authors:  A Pfennig; J Conell; P Ritter; D Ritter; E Severus; T D Meyer; M Hautzinger; J Wolff; F Godemann; A Reif; M Bauer
Journal:  Nervenarzt       Date:  2017-03       Impact factor: 1.214

9.  [Inhalative loxapine: old tried and trusted medication with new indications].

Authors:  G Juckel
Journal:  Nervenarzt       Date:  2013-09       Impact factor: 1.214

10.  Commentary on a recent review of lithium toxicity: what are its implications for clinical practice?

Authors:  Bruno Müller-Oerlinghausen; Michael Bauer; Paul Grof
Journal:  BMC Med       Date:  2012-11-02       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.